FINWIRES · TerminalLIVE
FINWIRES

Hut 8在美国盘前交易中上涨30%,此前该公司公布了一份价值98亿美元的合约;尽管营收增长,但第一季度亏损扩大。

By

-- 能源基础设施平台Hut 8(HUT.TO)周三宣布,已通过一项为期15年、价值98亿美元的租赁协议,将其位于德克萨斯州努埃塞斯县的Beacon Point数据中心园区一期项目商业化,租赁容量达352兆瓦(MW)。 该公司表示,尽管第一季度营收增长,但净亏损扩大。 Hut 8称,此次商业化后,租户——一家“高投资级公司”——将在该园区部署专用计算基础设施,以支持超大规模的人工智能训练和推理工作负载。 Hut 8表示,该园区将交付一个352兆瓦的人工智能工厂,该工厂采用NVIDIA的DSX参考架构,专为千兆瓦级人工智能基础设施而设计。 在交易亮点方面,该公司提到租赁结构为三方净租赁(NNN),并补充说,三个五年续约选择权将使合同潜在价值增加至约251亿美元(假设所有三个选择权均被行使)。 该公司表示,此次交易将Hut 8已签约的AI数据中心总容量扩展至597兆瓦,基本合同总价值约为168亿美元。 该公司表示:“Beacon Point是继River Bend之后,公司采用‘电力优先’的全新开发模式实现商业化的第二个AI数据中心园区。Hut 8已签署1000兆瓦公用容量的互联协议,预计将于2027年第一季度投入使用。” 该公司表示,首批数据机房预计将于2027年第三季度交付。 该公司指出,此次租赁的352兆瓦IT容量需要约500兆瓦的公用容量,标志着该园区商业化的第一阶段。该园区设计容量高达1000兆瓦,“为园区未来的扩张和收入增长提供了充足的空间”。 Hut 8 首席执行官 Asher Genoot 表示:“Beacon Point 项目凸显了我们为何以电力为核心,并保持跨终端市场的灵活性。跨多个应用领域的运营使我们能够承接单一用途开发商无法承接的资产,并随着需求的变化将其引导至更高价值的商业化路径。这种灵活性是我们有意为之,并已融入到我们承接、开发和商业化基础设施的方方面面。” Hut 8 表示,公司正与“德克萨斯州的主要利益相关者”合作开发 Beacon Point 园区,其中包括美国电力公司 (AEP) 的子公司 AEP Texas 和科珀斯克里斯蒂地区经济发展公司 (CCREDC)。 Hut 8 还补充道:“NVIDIA 作为技术合作伙伴参与其中,园区一期工程将采用 NVIDIA 的 DSX 参考架构,用于构建千兆瓦级人工智能工厂。全球领先的科学咨询公司 Jacobs 担任 EPCM(工程、采购和施工管理)负责人,与 Vertiv 携手为关键数字基础设施系统提供支持。” HUT 在其第一季度财报中表示,截至 2026 年 3 月 31 日的三个月内,净亏损为 2.531 亿美元,而去年同期净亏损为 1.343 亿美元。该公司表示,该期间的净亏损包括 2.957 亿美元,主要为数字资产的未实现亏损,而去年同期为 1.124 亿美元。 该公司表示,2026 年第一季度营收为 7100 万美元,而去年同期为 2180 万美元。FactSet 汇总的普遍预期为 7900 万美元。 该公司指出,由于 American Bitcoin 是其合并子公司,因此通过与 American Bitcoin 签订的管理服务协议、ASIC 托管协议和共享服务协议产生的所有收入均已在合并报表中扣除。 “随着River Bend项目朝着2027年第二季度交付的目标稳步推进,以及我们8375兆瓦的在建项目储备,我们的重点是继续以严谨的作风和卓越的品质扩大规模,我们相信正是这种作风和品质使我们的平台在市场中脱颖而出,”首席执行官补充道。“我们相信,我们成熟的商业模式、稳健的资产负债表以及公用事业规模的在建项目储备,将使我们能够继续以毫不妥协的严谨态度执行各项工作,打造我们认为在能源与科技交汇处能够持续发展、传承数代的企业。” 该公司在美国上市的股票在盘前交易中上涨32.6%,至106.75美元。

Related Articles

Research

Research Alert: CFRA Lifts View On Shares Of H.f. Sinclair To Buy From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $87, raised $31, reflects a combination of relative valuation and DCF models. On a relative basis, we apply a 7.0x multiple of enterprise value to projected 2027 EBITDA. The applied multiple is above DINO's historical forward average, but below peers. We think a modest discount to peers is reasonable on the basis of below-average return on invested capital. Still, a multiple above normal levels for DINO is also reasonable, because we think refining margins will be high in both 2026 and 2027. This approach yields a value of $85 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5%, 2% terminal growth, discounted at a WACC of 7.2%, yields intrinsic value of $89 per share. We lift our 2026 EPS estimate by $2.87 to $7.30 and 2027's by $1.66 to $6.26. In our view, DINO has above-average exposure to middle distillates, which is where we think refining margins will be relatively stronger. Shares yield 2.8%.

$DINO
US Markets

CVS Health Raises 2026 Outlook After First-Quarter Beat

CVS Health (CVS) raised its full-year earnings outlook after reporting better-than-expected first-quarter results driven by improvement in its health-care benefits segment.The company raised its 2026 adjusted earnings guidance to $7.30 to $7.50 a share from its previous projection of $7 to $7.20. The consensus on FactSet is $7.16."We are also updating our outlook for full-year cash flow from operations to at least $9.5 billion, reflecting improved underlying performance, primarily related to working capital in our health-care benefits segment," Chief Financial Officer Brian Newman said on the earnings call, according to a FactSet transcript.The stock jumped 7.3% in Wednesday trading and has gained 9.1% this year.CVS maintained its medical benefit ratio guidance, which represents the percentage of premiums spent on medical benefits."This outlook continues to maintain the same respectful and prudent view on medical cost trends until we have greater visibility into how those trends are developing in our pharmacy and consumer wellness segment," Newman said.In the first quarter, adjusted EPS rose to $2.57 from $2.25 a year earlier as revenue climbed 6.2% to $100.43 billion. Wall Street expected EPS of $2.18 on revenue of $94.97 billion.Sales in the health care benefits segment advanced 3.3% to $35.97 billion. "This increase was primarily driven by our government business, partially offset by our exit from the individual exchange business in 2026," Newman said.Revenue in the health-services segment rose 11% to $48.24 billion, while pharmacy and consumer wellness was little changed at $31.99 billion.Price: $86.61, Change: $+5.92, Percent Change: +7.34%

$CVS
Treasury

Canada's Advantages to Trade With The U.S. Are Difficult to Replace, Says Rosenberg Research

Canadian Prime Minister Mark Carney should start to think twice about cozying up to China and forging stronger links with the European Union, said Rosenberg Research after Tuesday's latest Canadian merchandise trade.The trade surplus with the United States in March more than doubled from $2.8 billion to a six-month high of $7.1 billion, noted Rosenberg Research.For all the "bellyaching" about all the negative trade actions, Canada's bilateral surplus of $7.1 billion today compares with $6.4 billion this time last year.Canada's long-standing trade reliance on the U.S. isn't going away despite Donald Trump, who has barely more than two years left in the presidential office, because all these attempts to diversify relationships aren't an antidote to the world's longest border, cheap transportation costs, and access to a $22 trillion consumer base, stated Rosenberg.

$$CXY